Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker.

Kaur ZP, Ochman AR, Mayer JP, Gelfanov VM, DiMarchi RD.

ACS Chem Biol. 2013 Aug 16;8(8):1822-9. doi: 10.1021/cb4002624. Epub 2013 Jun 18.

PMID:
23730814
2.

MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.

Saporito MS, Ochman AR, Lipinski CA, Handler JA, Reaume AG.

J Pharmacol Exp Ther. 2012 Jul;342(1):15-22. doi: 10.1124/jpet.112.192096. Epub 2012 Apr 3.

3.

The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.

Ochman AR, Lipinski CA, Handler JA, Reaume AG, Saporito MS.

J Pharmacol Exp Ther. 2012 Jul;342(1):23-32. doi: 10.1124/jpet.112.192187. Epub 2012 Mar 19.

4.

Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

Shetty RS, Lee Y, Liu B, Husain A, Joseph RW, Lu Y, Nelson D, Mihelcic J, Chao W, Moffett KK, Schumacher A, Flubacher D, Stojanovic A, Bukhtiyarova M, Williams K, Lee KJ, Ochman AR, Saporito MS, Moore WR, Flynn GA, Dorsey BD, Springman EB, Fujimoto T, Kelly MJ.

J Med Chem. 2011 Jan 13;54(1):179-200. doi: 10.1021/jm100659v. Epub 2010 Dec 2.

PMID:
21126027
5.

Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia.

Stewart SL, Querec TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klein-Szanto A, Hamilton TC, Patriotis C.

Cancer Res. 2004 Nov 15;64(22):8177-83.

Supplemental Content

Loading ...
Support Center